Pancreatic Cancer Initial Detection Via Liquid Biopsy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Liquid biopsy.
- Who it may be relevant to
- Registry conditions: Pancreatic Cancer, IPMN, Pancreatic, Individuals at Risk, Chronic Pancreatitis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Sweden
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas \[N0M0\]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).
Interventions
- Diagnostic test Liquid biopsy
Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for "ground truth"
Primary outcome measures
- Cancer detection [Time frame: Up to 4 weeks after surgery]
Secondary outcome measures (1)
- Overall survival [Time frame: 1 month - 24 months after surgical resection of the tumor]
Eligibility criteria
Inclusion criteria
- Suspicion of or elevated risk for pancreatic ductal adenocarcinoma (PDAC); intraductal papillary mucinous neoplasias (IPMN); individuals at risk (IAR) for pancreatic cancer
Exclusion criteria
- other malignant condition
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Sweden · 1 center
- Gastrocentrum, KarolinskaUniversity Hospital — Stockholm
Identifiers
NCT: NCT06283576 · PANCAID-00-08